Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poor Handling of Complaints, Contractors, Contamination Draw FDA Warning Letters

This article was originally published in The Gold Sheet

Executive Summary

Several warning letters FDA issued in January and February highlighted complaint handling issues, supply chain considerations and contamination-related concerns.
Advertisement

Related Content

Contamination and Raw Material Testing Issues Raised in FDA Warning Letters
FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011
Contamination Issues Drove Drug Recalls to Record Levels in 2011
FDA Warning Letters Hit Inadequate Investigations and QC Failings
FDA Warning Letters Hit Inadequate Investigations and QC Failings
Recall Roundup: tainted heparin, glass flakes, odorous bottles and more
Recall Roundup: tainted heparin, glass flakes, odorous bottles and more
Advertisement
UsernamePublicRestriction

Register

PS000584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel